Erica Franceschinis, Marco Roverso, Daniela Gabbia, Sara De Martin, Matteo Brusegan, Christian Vaccarin, Sara Bogialli, Adriana Chilin,
4,6,4'-trimethylangelicin (TMA) is a promising pharmacological option for the treatment of cystic fibrosis (CF) due to its triple-acting behavior toward the function of the CF transmembrane conductance regulator. It is a poorly water-soluble drug, and thus it is a candidate for developing a self-emulsifying formulation (SEDDS). This study aimed to develop a SEDDS to improve the oral bioavailability of TMA. Excipients were selected on the basis of solubility studies. Polyoxyl-35 castor oil (Cremophor® ...
Tópico(s): Cystic Fibrosis Research Advances
2022 - Multidisciplinary Digital Publishing Institute | Pharmaceutics